reference stringlengths 68 167 | prediction stringlengths 68 166 | wer float64 0 0.19 | cer float64 0 0.13 | entities stringlengths 91 124 | entity_cer float64 0 0.67 | audio audioduration (s) 5.01 16.1 |
|---|---|---|---|---|---|---|
Please evaluate Mr. Jones for eligibility for depemokimab, as he has severe eosinophilic asthma despite current therapy. | Please evaluate Mr. Jones for eligibility for dupemachimab, as he has severe eosinophilic asthma despite current therapy. | 0.058824 | 0.034188 | "[{\"text\": \"depemokimab\", \"category\": \"drug\", \"char_start\": 46, \"char_end\": 57}]" | 0.272727 | |
Abdominal ultrasound performed to assess liver parenchyma given patient's history of familial chylomicronemia syndrome and initiation of plozasiran. | Abdominal ultrasound performed to assess liver parenchyma given patient's history of familial chylomicronemia syndrome and initiation of plazosarin. | 0.055556 | 0.027211 | "[{\"text\": \"plozasiran\", \"category\": \"drug\", \"char_start\": 137, \"char_end\": 147}]" | 0.4 | |
Patients receiving donidalorsen demonstrated a significant reduction in the frequency of hereditary angioedema attacks during the study period. | Patients receiving Donadelorcin demonstrated a significant reduction in the frequency of hereditary angioedema attacks during the study period. | 0.055556 | 0.028169 | "[{\"text\": \"donidalorsen\", \"category\": \"drug\", \"char_start\": 19, \"char_end\": 31}]" | 0.416667 | |
Patient discharged with a prescription for tradipitant for motion sickness prevention. | Patient discharged with a prescription for tradipitant for motion sickness prevention. | 0 | 0 | "[{\"text\": \"tradipitant\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 54}]" | 0 | |
Initiate gepotidacin 1500 mg BID for three days for her acute uncomplicated cystitis. | Initiate gepatidacin 1500 mg bid for 3 days for her acute uncomplicated cystitis. | 0.153846 | 0.071429 | "[{\"text\": \"gepotidacin\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 20}]" | 0.090909 | |
Prescribe fitusiran, 80 mg subcutaneously once monthly, for bleeding prophylaxis in this patient with hemophilia B and inhibitors. | Prescribe fiducarin, 80 mg subcutaneously once monthly, for bleeding prophylaxis in this patient with hemophilia B and inhibitors. | 0.055556 | 0.031496 | "[{\"text\": \"fitusiran\", \"category\": \"drug\", \"char_start\": 10, \"char_end\": 19}]" | 0.444444 | |
Given his persistent symptoms from obstructive hypertrophic cardiomyopathy, we are referring him for a cardiology opinion regarding aficamten. | Given his persistent symptoms from obstructive hypertrophic cardiomyopathy, we are referring him for a cardiology opinion regarding a Fickhamton. | 0.111111 | 0.028571 | "[{\"text\": \"aficamten\", \"category\": \"drug\", \"char_start\": 132, \"char_end\": 141}]" | 0.222222 | |
Clinical history includes familial chylomicronemia syndrome, currently managed with olezarsen, presenting with epigastric discomfort. | Clinical history includes familial chylomicronemia syndrome, currently managed with olzarsen, presenting with epigastric discomfort. | 0.071429 | 0.007692 | "[{\"text\": \"olezarsen\", \"category\": \"drug\", \"char_start\": 84, \"char_end\": 93}]" | 0.111111 | |
Initiate levacetylleucine for the neurological manifestations of Niemann-Pick type C disease. | Initiate levesetilucine for the neurological manifestations of Niemann-Pick Type C disease. | 0.083333 | 0.054348 | "[{\"text\": \"levacetylleucine\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 25}]" | 0.3125 | |
Plan to initiate therapy with obecabtagene autoleucel for the patient's relapsed B-cell acute lymphoblastic leukemia. | Plan to initiate therapy with obcaptaging autolusel for the patient's relapsed B-cell acute lymphoblastic leukemia. | 0.125 | 0.051724 | "[{\"text\": \"obecabtagene autoleucel\", \"category\": \"drug\", \"char_start\": 30, \"char_end\": 53}]" | 0.26087 | |
The patient was randomized to receive inavolisib in combination with palbociclib and fulvestrant as per the study arm. | The patient was randomized to receive enavelizib in combination with palbuciclib and fulvestrant, as per the study arm. | 0.111111 | 0.034188 | "[{\"text\": \"inavolisib\", \"category\": \"drug\", \"char_start\": 38, \"char_end\": 48}]" | 0.3 | |
We plan to initiate sibeprenlimab for her IgA nephropathy to help reduce her significant proteinuria. | We plan to initiate cipranlimab for her IgA nephropathy to help reduce her significant proteinuria. | 0.066667 | 0.04 | "[{\"text\": \"sibeprenlimab\", \"category\": \"drug\", \"char_start\": 20, \"char_end\": 33}]" | 0.307692 | |
Topical beremagene geperpavec was discussed with the family as a potential treatment option for the patient's dystrophic epidermolysis bullosa wounds. | Topical berimaging jeppapaevec was discussed with the family as a potential treatment option for the patient's dystrophic epidermolysis bullosa wounds. | 0.1 | 0.04698 | "[{\"text\": \"beremagene geperpavec\", \"category\": \"drug\", \"char_start\": 8, \"char_end\": 29}]" | 0.285714 | |
Overall, the extent of metastatic disease remains stable on current zongertinib therapy. | Overall, the extent of metastatic disease remains stable on current zangotinib therapy. | 0.083333 | 0.034884 | "[{\"text\": \"zongertinib\", \"category\": \"drug\", \"char_start\": 68, \"char_end\": 79}]" | 0.272727 | |
Following surgical resection, we are initiating vorasidenib as adjuvant therapy for his IDH-mutant grade 2 astrocytoma. | Following surgical resection, we are initiating voracitinib as adjuvant therapy for his IDH mutant grade 2 astrocytoma. | 0.058824 | 0.025641 | "[{\"text\": \"vorasidenib\", \"category\": \"drug\", \"char_start\": 48, \"char_end\": 59}]" | 0.272727 | |
Prescribe paltusotine 30 mg orally once daily for ongoing management of her acromegaly. | Prescribe poltusartine 30 mg orally once daily for ongoing management of her acromegaly. | 0.076923 | 0.034884 | "[{\"text\": \"paltusotine\", \"category\": \"drug\", \"char_start\": 10, \"char_end\": 21}]" | 0.181818 | |
Brain MRI demonstrates no acute intracranial pathology to account for the patient's menopausal vasomotor symptoms, currently managed with elinzanetant. | Brain MRI demonstrates no acute intracranial pathology to account for the patient's menopausal vasomotor symptoms, currently managed with a linzanetant. | 0.105263 | 0.013423 | "[{\"text\": \"elinzanetant\", \"category\": \"drug\", \"char_start\": 138, \"char_end\": 150}]" | 0.083333 | |
Given the recent FDA approval, we plan to initiate the patient on doxecitine and doxribtimine for their thymidine kinase 2 deficiency. | Given the recent FDA approval, we plan to initiate the patient on doxycycline and doxriptamine for their thymidine kinase 2 deficiency. | 0.095238 | 0.045455 | "[{\"text\": \"doxecitine and doxribtimine\", \"category\": \"drug\", \"char_start\": 66, \"char_end\": 93}]" | 0.185185 | |
The patient received a single oral dose of zoliflodacin for the treatment of uncomplicated urogenital gonorrhea. | The patient received a single oral dose of Xalifladesin for the treatment of uncomplicated urogenital gonorrhea. | 0.0625 | 0.045045 | "[{\"text\": \"zoliflodacin\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 55}]" | 0.416667 | |
Considering his persistently elevated LDL despite maximal statin therapy, we are evaluating the potential for initiating lerodalcibep as a monthly subcutaneous option. | Considering his persistently elevated LDL despite maximal statin therapy, we are evaluating the potential for initiating liraglutide as a monthly subcutaneous option. | 0.045455 | 0.048485 | "[{\"text\": \"lerodalcibep\", \"category\": \"drug\", \"char_start\": 121, \"char_end\": 133}]" | 0.666667 | |
Datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival compared to standard of care in the study population. | Dadapartumab Derixtecan demonstrated a statistically significant improvement in progression-free survival compared to standard of care in the study population. | 0.1 | 0.038217 | "[{\"text\": \"Datopotamab deruxtecan\", \"category\": \"drug\", \"char_start\": 0, \"char_end\": 22}]" | 0.272727 | |
Patient discharged on nerandomilast 25 mg twice daily for continued management of her idiopathic pulmonary fibrosis. | Patient discharged on narendamolast 25 mg twice daily for continued management of her idiopathic pulmonary fibrosis. | 0.0625 | 0.034783 | "[{\"text\": \"nerandomilast\", \"category\": \"drug\", \"char_start\": 22, \"char_end\": 35}]" | 0.307692 | |
The patient was discharged on resmetirom for their noncirrhotic MASH with moderate liver fibrosis, per recent EMA approval. | The patient was discharged on resmetirom for their non-cirrhotic MASH with moderate liver fibrosis, per recent EMA approval. | 0.111111 | 0.008264 | "[{\"text\": \"resmetirom\", \"category\": \"drug\", \"char_start\": 30, \"char_end\": 40}]" | 0 | |
Start penpulimab 200 mg IV every three weeks for recurrent nasopharyngeal carcinoma. | Start pembrolizumab 200 mg IV every 3 weeks for recurrent nasopharyngeal carcinoma. | 0.166667 | 0.13253 | "[{\"text\": \"penpulimab\", \"category\": \"drug\", \"char_start\": 6, \"char_end\": 16}]" | 0.3 | |
Initiate ziftomenib 200 mg orally once daily for relapsed NPM1-mutated AML, monitoring for differentiation syndrome. | Initiate ziftomib 200 mg orally once daily for relapsed NPM1-mutated AML, monitoring for differentiation syndrome. | 0.0625 | 0.017544 | "[{\"text\": \"ziftomenib\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 19}]" | 0.2 | |
No acute changes demonstrated on orbital CT; patient continues acoltremon for chronic dry eye disease. | No acute changes demonstrated on orbital CT. Patient continues aciltremen for chronic dry eye disease. | 0.066667 | 0.02 | "[{\"text\": \"acoltremon\", \"category\": \"drug\", \"char_start\": 63, \"char_end\": 73}]" | 0.2 | |
Clinical history notes IgA nephropathy with significant proteinuria, for which the patient recently initiated atrasentan. | Clinical history notes IgA nephropathy with significant proteinuria, for which the patient recently initiated Atracenton. | 0.066667 | 0.016807 | "[{\"text\": \"atrasentan\", \"category\": \"drug\", \"char_start\": 110, \"char_end\": 120}]" | 0.3 | |
Follow-up MRI of the lower extremities performed to assess disease progression in a Duchenne patient receiving givinostat. | Follow-up MRI of the lower extremities performed to assess disease progression in a Duchenne patient receiving givanostat. | 0.055556 | 0.008264 | "[{\"text\": \"givinostat\", \"category\": \"drug\", \"char_start\": 111, \"char_end\": 121}]" | 0.1 | |
We are referring Mr. Smith for consideration of telisotuzumab vedotin given his locally advanced non-squamous NSCLC with high c-Met overexpression. | We are referring Mr. Smith for consideration of Telesotuzumab Vedetin, given his locally advanced non-squamous NSCLC with high c-Met overexpression. | 0.090909 | 0.013793 | "[{\"text\": \"telisotuzumab vedotin\", \"category\": \"drug\", \"char_start\": 48, \"char_end\": 69}]" | 0.190476 | |
We are considering garadacimab for prophylaxis to prevent further hereditary angioedema attacks in this patient. | We are considering gareidasumab for prophylaxis to prevent further hereditary angioedema attacks in this patient. | 0.066667 | 0.036036 | "[{\"text\": \"garadacimab\", \"category\": \"drug\", \"char_start\": 19, \"char_end\": 30}]" | 0.272727 | |
We are considering initiating narsoplimab for her refractory transplant-associated thrombotic microangiopathy. | We are considering initiating narsoplimab for her refractory transplant-associated thrombotic microangiopathy. | 0 | 0 | "[{\"text\": \"narsoplimab\", \"category\": \"drug\", \"char_start\": 30, \"char_end\": 41}]" | 0 | |
Patient discharged with a prescription for suzetrigine 50 mg twice daily for ongoing acute pain management. | Patient discharged with a prescription for Suzitrijin 50 mg twice daily for ongoing acute pain management. | 0.0625 | 0.028302 | "[{\"text\": \"suzetrigine\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 54}]" | 0.363636 | |
Prescribe sebetralstat 80 mg by mouth as needed for acute hereditary angioedema attacks. | Prescribe cebitralstat 80 mg by mouth as needed for acute hereditary angioedema attacks. | 0.076923 | 0.022989 | "[{\"text\": \"sebetralstat\", \"category\": \"drug\", \"char_start\": 10, \"char_end\": 22}]" | 0.166667 | |
Patient was started on delgocitinib cream for her moderate-to-severe chronic hand eczema due to inadequate response to previous topical treatments. | Patient was started on delgocitinib cream for her moderate to severe chronic hand eczema due to inadequate response to previous topical treatments. | 0 | 0 | "[{\"text\": \"delgocitinib\", \"category\": \"drug\", \"char_start\": 23, \"char_end\": 35}]" | 0 | |
Patients receiving dordaviprone demonstrated a statistically significant improvement in overall survival compared to placebo. | Patients receiving dordoviprone demonstrated a statistically significant improvement in overall survival compared to placebo. | 0.071429 | 0.008065 | "[{\"text\": \"dordaviprone\", \"category\": \"drug\", \"char_start\": 19, \"char_end\": 31}]" | 0.083333 | |
Stable disease noted in the setting of ongoing avutometinib therapy. | stable disease noted in the setting of ongoing avutamatinib therapy. | 0.1 | 0.029851 | "[{\"text\": \"avutometinib\", \"category\": \"drug\", \"char_start\": 47, \"char_end\": 59}]" | 0.166667 | |
Patients in cohort A received a single infusion of etuvetidigene autotemcel following myeloablative conditioning. | Patients in Cohort A received a single infusion of etuvetadigene autotemsyl following myeloablative conditioning. | 0.142857 | 0.026786 | "[{\"text\": \"etuvetidigene autotemcel\", \"category\": \"drug\", \"char_start\": 51, \"char_end\": 75}]" | 0.125 | |
No acute intracranial hemorrhage or significant lymphadenopathy is identified in this patient with Wiskott-Aldrich syndrome. | No acute intracranial hemorrhage or significant lymphadenopathy is identified in this patient with Wiskott-Aldrich syndrome. | 0 | 0 | "[{\"text\": \"Wiskott-Aldrich syndrome\", \"category\": \"condition\", \"char_start\": 99, \"char_end\": 123}]" | 0 | |
We are referring this patient for allogeneic hematopoietic stem cell transplantation, and recommend a preparative conditioning regimen including treosulfan. | We are referring this patient for allogeneic hematopoietic stem cell transplantation and recommend a preparative conditioning regimen including triosulfan. | 0.052632 | 0.006494 | "[{\"text\": \"treosulfan\", \"category\": \"drug\", \"char_start\": 145, \"char_end\": 155}]" | 0.1 | |
We are evaluating aceclidine as a potential non-surgical treatment for her symptomatic presbyopia to enhance near vision. | We are evaluating a ceclydine as a potential non-surgical treatment for her symptomatic presbyopia to enhance near vision. | 0.111111 | 0.016667 | "[{\"text\": \"aceclidine\", \"category\": \"drug\", \"char_start\": 18, \"char_end\": 28}]" | 0.1 | |
Plan for Meduloc intramedullary fixation of the right fifth metacarpal shaft fracture. | Plan for medullar-intramedullary fixation of the right 5th metacarpal shaft fracture. | 0.166667 | 0.070588 | "[{\"text\": \"Meduloc intramedullary fixation\", \"category\": \"procedure\", \"char_start\": 9, \"char_end\": 40}]" | 0.129032 | |
Given the diagnosis of H3 K27M-mutant diffuse midline glioma, please prescribe dordaviprone as per protocol. | Given the diagnosis of H3K27M mutant diffuse midline glioma, please prescribe dordoviprone as per protocol. | 0.1875 | 0.018868 | "[{\"text\": \"H3 K27M-mutant diffuse midline glioma\", \"category\": \"condition\", \"char_start\": 23, \"char_end\": 60}]" | 0.054054 | |
No new intracranial abnormalities are identified following the initiation of sepiapterin. | No new intracranial abnormalities are identified following the initiation of Cepiaptarin. | 0.090909 | 0.022727 | "[{\"text\": \"sepiapterin\", \"category\": \"drug\", \"char_start\": 77, \"char_end\": 88}]" | 0.181818 | |
Initiate pembrolizumab and berahyaluronidase alfa subcutaneously for her metastatic lung adenocarcinoma. | Initiate pembrolizumab and birahialuronidase-alpha subcutaneously for her metastatic lung adenocarcinoma. | 0.181818 | 0.038835 | "[{\"text\": \"pembrolizumab and berahyaluronidase alfa\", \"category\": \"drug\", \"char_start\": 9, \"char_end\": 49}]" | 0.1 | |
Eligible subjects with inoperable plexiform neurofibromas due to neurofibromatosis type 1 were randomized to mirdametinib or placebo. | Eligible subjects with inoperable plexiform neurofibromas due to neurofibromatosis type 1 were randomized to merdometinib or placebo. | 0.058824 | 0.015152 | "[{\"text\": \"mirdametinib\", \"category\": \"drug\", \"char_start\": 109, \"char_end\": 121}]" | 0.166667 | |
Eligibility for dordaviprone required confirmation of the H3 K27M histone mutation in patients with diffuse midline glioma. | Eligibility for dordiviprone required confirmation of the H3K27M histone mutation in patients with diffuse midline glioma. | 0.176471 | 0.016393 | "[{\"text\": \"H3 K27M histone mutation\", \"category\": \"biomarker\", \"char_start\": 58, \"char_end\": 82}]" | 0.041667 | |
Patient will be discharged on oral elamipretide 40 mg twice daily for his Barth syndrome, with close follow-up. | Patient will be discharged on oral elamipretide 40 mg twice daily for his Barth syndrome, with close follow-up. | 0 | 0 | "[{\"text\": \"elamipretide\", \"category\": \"drug\", \"char_start\": 35, \"char_end\": 47}]" | 0 | |
Start sevabertinib 150 mg PO BID for HER2-mutated NSCLC with CNS metastases. | Start cevibertinib 150 mg PO BID for HER2 mutated NSCLC with CNS metastases. | 0.076923 | 0.026667 | "[{\"text\": \"sevabertinib\", \"category\": \"drug\", \"char_start\": 6, \"char_end\": 18}]" | 0.166667 | |
Follow-up CT scan demonstrates stable osseous disease, indicating a persistent response to linvoseltamab treatment. | Follow-up CT scan demonstrates stable osseous disease, indicating a persistent response to linvoseltamab treatment. | 0 | 0 | "[{\"text\": \"linvoseltamab\", \"category\": \"drug\", \"char_start\": 91, \"char_end\": 104}]" | 0 | |
The patient is discharged home to continue sunvozertinib 300 mg daily for their EGFR exon 20 insertion mutated NSCLC. | The patient is discharged home to continue sonvosertinib 300 mg daily for their EGFR exon 20 insertion mutated NSCLC. | 0.052632 | 0.017241 | "[{\"text\": \"sunvozertinib\", \"category\": \"drug\", \"char_start\": 43, \"char_end\": 56}]" | 0.153846 |
Evaluation Results: universal-3-pro
Evaluation results from Whisper model evaluation.
Summary
| Model | WER | CER |
|---|---|---|
| assemblyai/universal-3-pro | 6.91% | 2.40% |
Source Data
- Evaluation Dataset: Trelis/medical-terms-2025
- Model Evaluated: assemblyai/universal-3-pro
Columns
| Column | Description |
|---|---|
audio |
Audio sample (if available from source dataset) |
reference |
Ground truth transcription |
prediction |
Model prediction |
wer |
Word Error Rate for this sample |
cer |
Character Error Rate for this sample |
| entities | Entity annotations from source dataset |
| entity_cer | Per-sample entity CER (-1.0 if no entities) |
Entity CER
Overall Entity CER: 18.06%
| Category | CER |
|---|---|
| biomarker | 4.17% |
| condition | 3.28% |
| drug | 20.33% |
| procedure | 12.90% |
Generated by Trelis Studio
- Downloads last month
- 17